Although benralizumab currently lacks the indication for the treatment of CRSwNP, growing evidence indicates that the anti-IL-5R has a positive impact on nasal symptoms in comorbid patients [42,43,44,45]. This evidence concerns the gene IL5RA and chronic rhinosinusitis with nasal polyps.